Fangda advises on Vazyme SSE STAR Market listing

On November 15, 2021, Nanjing Vazyme Biotech Co., Ltd. (stock code: 688105, “Vazyme”) successfully listed on the STAR Market of the Shanghai Stock Exchange. Vazyme issued a total of 40.01 million shares, raising a total of about RMB2.2 billion. Vazyme is the first biological reagent company to be listed on the SSE STAR Market.

    Vazyme researches and develops technology and products focusing on functional proteins, such as enzymes, antigens, antibodies, and polymer organic materials. It is regarded as one of the few domestic R&D innovative enterprises that have capabilities of both independent and controllable upstream technology development and terminal product production in China.

      Vazyme owns more than 200 types of genetic engineering recombinant enzyme and 1,000 high-performance antigens and monoclonal antibodies. In addition, the company owns more than 500 products that are widely applied to science research, high-throughput sequencing, in vitro diagnosis (IVD), pharmaceutical and vaccine research development, animal quarantine and other fields.

        After the outbreak of the COVID-19 epidemic, Vazyme helped in the drive to limit the global spread of the disease through developing detection kits and neutralizing antibody drugs, among other biological breakthroughs.

          Fangda acted as the legal counsel to the sole sponsor and lead underwriter, Huatai United Securities, and participated in the whole process of Vazyme’s SSE STAR Market issuance and listing. The team was led by partners Qiang Ma and Wanhua Huo, and team members included Kevin Liu, Shirley Feng, Xinyu Guo, Haiying Wang, and Anna Wu.